# Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention:  Guidance for Industry – FDA Guidance

Source: https://www.keypedia.com/guidances/guidance-document/clostridioides-difficile-infection-developing-drugs-for-treatment-reduction-of-recurrence-and-prevention-guidance-for-industry/ffcc278f-6d9f-40a2-8bf5-46599aad2a4a

> FDA guidance document: Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention:  Guidance for Industry. Issue date: May 08, 2026. Get complete insights and analysis.

---

## Details

- Title: Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention:  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2026-05-08
- Last Changed: 2026-05-08
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2022-D-1261">FDA-2022-D-1261</a>

## Related Documents

- [Statistical Approaches to Establishing Bioequivalence](https://www.keypedia.com/guidances/guidance-document/statistical-approaches-to-establishing-bioequivalence/a8edefbb-b408-432b-b325-d7df8cf98214)
- [Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs](https://www.keypedia.com/guidances/guidance-document/physicochemical-and-structural-q3-characterization-of-topical-drug-products-submitted-in-andas/9120d697-9a7d-4aac-b9ff-98ee81aafa56)
- [Pulmonary Tuberculosis: Developing Drugs for Treatment:  Guidance for Industry](https://www.keypedia.com/guidances/guidance-document/pulmonary-tuberculosis-developing-drugs-for-treatment-guidance-for-industry/c3b04c05-0fb6-49b6-93c3-acb835649031)